MA34525B1 - NEW HEMATOPOIETIC GROWTH FACTOR CONJUGATE G-CSF AND POLYETHYLENE GLYCOL - Google Patents

NEW HEMATOPOIETIC GROWTH FACTOR CONJUGATE G-CSF AND POLYETHYLENE GLYCOL

Info

Publication number
MA34525B1
MA34525B1 MA35731A MA35731A MA34525B1 MA 34525 B1 MA34525 B1 MA 34525B1 MA 35731 A MA35731 A MA 35731A MA 35731 A MA35731 A MA 35731A MA 34525 B1 MA34525 B1 MA 34525B1
Authority
MA
Morocco
Prior art keywords
csf
growth factor
conjugate
hematopoietic growth
polyethylene glycol
Prior art date
Application number
MA35731A
Other languages
French (fr)
Inventor
Dmitriy Valentinovich Morozov
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Elena Leonidovna Morozova
Tatyana Veniaminovna Chernovskaya
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34525(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of MA34525B1 publication Critical patent/MA34525B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES AGENTS PHARMACEUTIQUES ET UN MÉDICAMENT, À SAVOIR, DE NOUVEAUX CONJUGUÉS PHYSIOLOGIQUEMENT ACTIFS DU FACTEUR DE CROISSANCE HÉMATOPOÏÉTIQUE G-CSF REPRÉSENTÉ PAR LA FORMULE GÉNÉRALE (I) DANS LAQUELLE : N DÉSIGNE DES ENTIERS DE 681 À 1 000; M DÉSIGNE UN ENTIER > 4; NAH-G-CSFDÉSIGNE UN POLYPEPTIDE NATUREL OU RECOMBINANT, AYANT L'ACTIVITÉ DE G-CSF. L'INVENTION CONCERNE EN OUTRE DES MÉDICAMENTS CONTENANT LE CONJUGUÉ DE FORMULE (I) REVENDIQUÉ, DES COMPOSITIONS PHARMACEUTIQUES, L'UTILISATION D'UN CONJUGUÉ DE FORMULE (I) POUR DES AGENTS PHARMACEUTIQUES ET DES MÉDICAMENTS PRÉSENTANT LE FACTEUR DE CROISSANCE HÉMATOPOÏÉTIQUE G-CSF EN TANT QUE SUBSTANCE ACTIVE, DES APPROCHES POUR PRÉVENIR ET/OU TRAITER LA NEUTROPÉNIE, LE CONTENANT QUI COMPREND LA COMPOSITION PHARMACEUTIQUE.THE INVENTION INVOLVES PHARMACEUTICAL AGENTS AND A MEDICAMENT, IE, NEW PHYSIOLOGICALLY ACTIVE CONJUGATES OF THE G-CSF HEMATOPOIETIC GROWTH FACTOR REPRESENTED BY THE GENERAL FORMULA (I) IN WHICH: N DESIGNATES WHOLE ENTIREES FROM 681 TO 1000; M DESCRIBES AN ENTIRE> 4; NAH-G-CSF IS A NATURAL OR RECOMBINANT POLYPEPTIDE HAVING G-CSF ACTIVITY. The invention also relates to medicaments containing the conjugate of formula (I) claimed, pharmaceutical compositions, the use of a conjugate of formula (I) for pharmaceutical agents and medicinal products having the haemato-trophic growth factor G-CSF. AS AN ACTIVE SUBSTANCE, APPROACHES TO PREVENT AND / OR TREAT NEUTROPENIA, THE CONTAINER WHICH COMPRISES THE PHARMACEUTICAL COMPOSITION.

MA35731A 2010-08-13 2011-07-19 NEW HEMATOPOIETIC GROWTH FACTOR CONJUGATE G-CSF AND POLYETHYLENE GLYCOL MA34525B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent
PCT/RU2011/000532 WO2012021088A1 (en) 2010-08-13 2011-07-19 A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol

Publications (1)

Publication Number Publication Date
MA34525B1 true MA34525B1 (en) 2013-09-02

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35731A MA34525B1 (en) 2010-08-13 2011-07-19 NEW HEMATOPOIETIC GROWTH FACTOR CONJUGATE G-CSF AND POLYETHYLENE GLYCOL

Country Status (17)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
RU2650962C2 (en) 2012-06-07 2018-04-18 Чилдрен'З Хоспитал Лос Анджелес Methods for treating neutropenia using retinoid agonists
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
EP3107533A4 (en) 2014-02-18 2017-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
PE20220371A1 (en) 2014-07-14 2022-03-16 Gennova Biopharmaceuticals Ltd NOVEL PROCEDURE FOR PURIFICATION OF rHU-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
CN115297844A (en) * 2020-03-17 2022-11-04 德拉格雷丘尔公司 Liquid formulation of GM-CSF for inhalation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135370T1 (en) * 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
ES2397712T3 (en) * 2006-01-18 2013-03-08 Qps, Llc Pharmaceutical compositions with reinforced stability
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease

Also Published As

Publication number Publication date
CN103140499A (en) 2013-06-05
EA019043B1 (en) 2013-12-30
EA201101035A1 (en) 2012-02-28
PE20131085A1 (en) 2013-10-10
CR20130020A (en) 2013-02-20
RS20130094A1 (en) 2013-08-30
CN103140499B (en) 2014-12-17
WO2012021088A1 (en) 2012-02-16
DOP2013000003A (en) 2013-07-31
RU2446173C1 (en) 2012-03-27
CL2013000400A1 (en) 2013-07-26
CO6670557A2 (en) 2013-05-15
SG187572A1 (en) 2013-03-28
NI201300007A (en) 2014-05-26
KR20130043167A (en) 2013-04-29
ECSP13012399A (en) 2013-05-31
CU20130012A7 (en) 2013-04-19
MY160732A (en) 2017-03-15
CU24139B1 (en) 2015-12-23
KR101549457B1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
MA34525B1 (en) NEW HEMATOPOIETIC GROWTH FACTOR CONJUGATE G-CSF AND POLYETHYLENE GLYCOL
Singh et al. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with ‘standard of care’medicinal and procedures not requiring regulatory approval for use
Falanga et al. Peptides and dendrimers: How to combat viral and bacterial infections
KR101420034B1 (en) Topical co-enzyme q10 formulations and methodns of use
Zhang et al. Pharmacokinetic interaction between JBP485 and cephalexin in rats
NZ581589A (en) Solubilized sterile injectable formulation of docetaxel without Tween 80
WO2011038278A3 (en) Micelle encapsulation of therapeutic agents
US20090137527A1 (en) Compositions and methods for modulating immune function
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
MA38544A1 (en) Compositions of active pharmaceutical ingredients containing monoethyl ether and diethylene glycol or other alkyl derivatives
RU2013121788A (en) HIV REPLICATION INHIBITORS
MA33608B1 (en) Pharmaceutical composition, dosage form, preparation and treatment methods and use
US10864188B2 (en) Anti-microbial composition
EA201100809A1 (en) NEW functionally active, highly purified, stable Alpha interferon conjugate with polyethylene glycol, represented by one of positional isomers of PEG-NαH-IFN, with a reduced immunogenicity, with a prolonged biological effect are suitable for medical applications, and immunobiological agent based on ITS
JP6806685B2 (en) Compositions and Methods for Treating Acute Radiation Syndrome
Wang et al. In vitro and in vivo efficacies of novel carbazole aminoalcohols in the treatment of cystic echinococcosis
Cheng et al. Ursolic acid alleviates lipid accumulation by activating the AMPK signaling pathway in vivo and in vitro
Sadeghian et al. TAT-mediated intracellular delivery of carboxypeptidase G2 protects against methotrexate-induced cell death in HepG2 cells
NZ702342A (en) Pharmaceutical formulation
Guo et al. Salvianic acid A protects L-02 cells against γ-irradiation-induced apoptosis via the scavenging of reactive oxygen species
TW201216970A (en) Pharmaceutical composition for inhibiting inflammation
CN103874490A (en) Combinations of corroles and statins
KR101585795B1 (en) Preservative composition containing diethylene glycol monobenzyl ether as an active ingredient
JP2015537027A (en) Methods for treating patients infected with HIV and HTLV
Ismaiel et al. Modulation of nephrotoxicity induced by gentamicin with bone marrow mesenchymal stem cells and moringa oleifera extract